EUDA Health Holdings Limited (EUDAW) Analyse boursière

Présentation de l'entreprise

EUDA Health Holdings Limited operates primarily as a provider of non-invasive healthcare services, with its operational footprint concentrated in Singapore, Malaysia, and China. The company's service portfolio includes specialized medical interventions such as bioenergy capsules, stem cell therapy, CRISPR gene editing treatments, and the sale of dietary supplements, alongside property management services. While specific sector and industry classifications are not explicitly defined in available public data, the business model suggests a focus on emerging medical technologies and wellness solutions. The firm employs a workforce of 117 individuals to support these diverse service lines. Although the market capitalization and price-to-sales ratio are not available for calculation, the reported annual revenue of $5.16 million provides a tangible measure of the company's current scale. The presence of negative price-to-book metrics further indicates the company's financial positioning relative to its tangible assets. These financial figures collectively suggest that EUDA Health is a mid-sized entity within its niche, utilizing a relatively lean workforce to generate revenue across multiple therapeutic areas. The gap between available cash reserves and total debt obligations highlights the capital intensity required to sustain operations in the healthcare technology sector.

Santé financière

EUDA Health Holdings Limited reported a trailing twelve-month revenue of $5.16 million, yet this revenue generated a net loss of $2,064,341, resulting in an EBITDA of $-1,992,526. The substantial disparity between the positive revenue figure and the significant negative net income reveals a cost structure where operating expenses and cost of goods sold exceed gross profits, leading to an overall operating deficit. The company's free cash flow stood at $-3,350,164, indicating that cash outflows for capital expenditures and working capital needs surpassed cash generated from operations, which limits immediate financial flexibility for discretionary spending or debt reduction. Margin analysis shows a gross margin of 22.4%, suggesting that the company retains a moderate portion of revenue after direct production costs, while the operating margin of -37.0% and profit margin of 5.2% (calculated based on reported net income figures) illustrate the severe pressure on operational efficiency and the inability to convert revenue into operating profit. The balance sheet presents a conservative stance on leverage in terms of absolute debt levels, with total debt of $2.28 million, yet this is contrasted by a cash balance of only $176,584. The debt-to-equity ratio is not explicitly calculable from the provided data, but the negative price-to-book ratio of -0.01 suggests the company's market value is below its book value, a common trait for private or pre-profitability firms. Liquidity is constrained, as evidenced by a current ratio of 0.23, which indicates that current assets are insufficient to cover current liabilities without external financing or asset liquidation. Return on equity is not available for calculation, but the return on assets stands at -63.9%, a metric that reveals management has not yet achieved profitability in utilizing the company's asset base to generate returns for shareholders.

Évaluation de la valorisation

Trailing P/E, forward P/E, and price-to-sales ratios are not available for calculation due to the company's lack of positive net income and missing sales-to-market-cap data. The absence of a trailing P/E implies that traditional earnings-based valuation multiples are currently inapplicable, while the price-to-book ratio of -0.01 indicates a market price that is theoretically below the company's book value per share. Since EV/EBITDA and price-to-sales data are unavailable, alternative valuation metrics cannot be derived to suggest a premium or discount relative to peers. The stock's price metrics show a 52-week high of $0.03 and a 52-week low of $0.03, meaning the current trading price is effectively trading at 0% above the 52-week high and 0% below the 52-week low. The beta value of 0.16 suggests that the stock exhibits significantly lower volatility relative to the broader market, moving with less intensity than the general equity index. This low beta value, combined with the narrow price range between the 52-week high and low, indicates that the share price has experienced minimal fluctuation over the past year. The lack of earnings growth data further complicates the valuation picture, as investors cannot rely on earnings trajectory to justify the current market price.

Growth & Income

Revenue growth year-over-year is reported at 60.2%, reflecting a strong expansion in top-line sales, whereas earnings growth year-over-year is not available due to the company's recent net losses. The inability to calculate earnings growth relative to revenue implies that the company is in a growth phase where top-line expansion precedes profitability, a common pattern for biotech or healthcare firms investing heavily in R&D and market penetration. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, instead choosing to reinvest all available earnings and cash flow back into the business to fund operations and future growth initiatives. This reinvestment strategy is necessitated by the negative free cash flow and operating losses, preventing the company from returning capital to shareholders. The overall growth profile is characterized by robust revenue expansion that has not yet translated into positive earnings, while the income profile is defined by the absence of dividend payments and reliance on capital appreciation potential.